Ypsomed sells its diabetes business and grows by over 35%

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 21.05.2025, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trajectory and achieved consolidated sales of CHF 748.9 million in the financial year 2024/25 (prior year: CHF 548.5 million). Adjusted for the divested pen needle and blood glucose monitoring business and other one-off effects, this represents 37.9% growth or CHF 193.0 million, in line with guidance. Reported operating profit (EBIT) was CHF 112.9 million (prior year: CHF 86.2 million). Adjusted for one-off effects, EBIT in line with guidance reached CHF 140.5 million, representing 42.5% growth. Net profit increased by CHF 9.1 million to CHF 87.5 million (prior year: CHF 78.4 million). Ypsomed has signed an agreement to sell its Diabetes Care business and will now concentrate on expanding its leading position in the Delivery Systems business.

Read more...

Ypsomed sells its diabetes care business to TecMed AG to become a pure play self-injection specialist

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX:YPSN) and TecMed AG (TecMed) have entered into an agreement for the sale of Ypsomed diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. Ypsomed is focusing on strengthening its leading position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies.

Read more...

Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million). 

Read more...

Ypsomed significantly increases its operating profit and plans to have two independent business areas

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 548.5 million in the financial year 2023/24 (previous year: CHF 497.5 million). Adjusted for the sale of the diabetes specialist DiaExpert, this corresponds to growth of 24.5 % or CHF 108.0 million. The operating profit (EBIT) amounted to CHF 86.2 million (previous year: CHF 60.6 million). Adjusted for the previous year's contribution from DiaExpert, this results in EBIT growth of CHF 46.8 million or 119 %. On this basis, Ypsomed was able to more than double its EBIT for the second time in a row. Net profit increased by more than half and now amounts to CHF 78.4 million (previous year: CHF 51.3 million). In future, Ypsomed intends to focus on expanding its leading position in Delivery Systems. To this purpose, it is examining strategic options for the Diabetes Care business area.

Read more...

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of a unique pen needle offering. With this step, Ypsomed is focusing its diabetes care business even more strongly on the further development and marketing of the innovative mylife Loop insulin pump solution. As part of its growth strategy, Ypsomed will invest over CHF 100 million over the next four years in the expansion of capacities for autoinjectors at the Solothurn site.

Read more...